×
About 205,578 results

ALLMedicine™ Detailed topics Center - News

Super-spreading events and contribution to transmission of MERS, SARS, and SARS-CoV-2 (COVID-19)
https://www.journalofhospitalinfection.com/article/S0195-6701(20)30177-8/fulltext

There is no clear definition for the term ‘super-spreader’ or ‘super-spreading event’. The World Health Organization refers to a super-spreader as a patient (or an event) that may transmit infection to a larger number of individuals than is usual by one individual (or event). In the severe acute respiratory syndrome (SARS) situation, a super-spreading event was defined as the transmission of SA...

Joint GI society message: COVID-19 clinical insights for our community of gastroenterologists and gastroenterology care providers
https://gastro.org/press-releases/joint-gi-society-message-covid-19-clinical-insights-for-our-community-of-gastroenterologists-and-gastroenterology-care-providers/

The situation involving the COVID-19 pandemic continues to evolve. There is recent evidence suggesting the potential for coronavirus transmission through droplets and perhaps fecal shedding1,2 posing potential risks during endoscopy and colonoscopy to other patients, endoscopy personnel and ourselves. We provide below important information as well as recommendations to consider in your insti...

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

Antibody Detection and Dynamic Characteristics in Patients with COVID-19
https://watermark.silverchair.com/ciaa461.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAABEYwggRCBgkqhkiG9w0BBwagggQzMIIELwIBADCCBCgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQML-2UYyGMp5__74HZAgEQgIID-VP47852zLLsLFFHC7k2obWGvI27loF7mFx6ccaQRjbwhuQIGLnPxwfOQMeFlfFVAFZAKa4ln4Zu8tJ4pyMAe_0DpNoBtNd7J4G248ZywRygT0RWAeDM9E0oxYYaVyNIeQYIseOEQYJljSdOjlMeT7rTXn_bjWG0XgnM4hcKG5vdzeeNaCMClYAUcNlvEL_JhqOEsouWaE1P2B6rwqyTQFevO_P6IUOHYMipr0kA7hT7Ei4R5HE-BRVNatcJs-QWZFqwXdbArSLOVckkOr84O73LZ9FLbR5nLxG59zI_JfXk_xBxRbftrCAY82kgfXjxdLd6WtGY-zDY52Y_gWhhwd3JZ9gZaBX9zxT_0V9epseHguRBD3_DNexdrwZ2RhzcN6GxeRTnJORFqFEB-0haDPa3s7zgZtQJtEzYGzo3380CI2d0J1GZeI8tZNGHhwvdKAxrpqb6oSYjIH41u6eLPgQwoyg6DAJISSL8pfDZWcc5ILKQYGy4HMlL9PqKv2J8Py1NaFNHiTPFlPN6VbRBGUxT_dWyspgerDc3V6bD2Spr6Q68vQEgz1L4eF9DOWDLKrCmBC00e2m7kMAGQ9PXPGalQBCNClMflQvj4s4itOfBrdOxfMgRb2jeVcK0wv28oBg0L4a1mxhUbBb6vVY4AqAwBgMaxZxxHxyBfRJBdWr3bk3S8ow5-UAFEXFxMwShRR3Wp5wxiZ5kv_hs4ZW8ycXC-Lc77qCSHqpgGl3qFJsakyjlalhF1AUMNo7Suj6HtWtYUKiQHe3hgZiFI6T9Up8hIhYPkoQNKd3v5jmzZl0YF7oEeqrOVoD6mOC5tRBnY1EE1eS53CHCCuCpxwEkES6BWHb-P0YzfM4SSpQlNCXZUxxHXnlmWZoNz9KVqXL-zm6x7dlG7Qd-hjsFoN4wn8h_THDZh3XgbL2CGCnKkRVBYJuMhz7iavKFHzogXUfP0U9zGcYLYS1wDBvTrkEU94n3sHbZejRFqQ14dVg-A3cep6o4d8H8p5mw1AvkSzp-s-NR2tjiJ66nTR9v_urbFGMSnlfo8lk5HH3DtZUG1KHCx0Lp626rmX0IXV2SxetMQCV7AXLRHmG-xa_67N74Lmkiqho2p6RkYiKtrkTZ-6h8ykKhwa0DfdbB1FrDRADlwOk8CnaUfNeiWtw82AoyQjWP6BMkIxgm-mZ3hV7heeH0RB73ES7OLUR2C1R2hyyt21cSo2Ub0jugp9-Gk5asCWsi8XKK7bubNP3D7vD0N2VdLkO1ZT969XyveN0soj5BYAbe7XMzPuf8dA8JfX86duPXjnnPG4qrvRS2NhaObrb-M_t5xa2VxIlTYcXNlnmTpkV7VnSyTqki_w

The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the COVID-19. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.

Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
https://www.nejm.org/doi/full/10.1056/NEJMc070348
The New England Journal of Medicine;

Previous studies have demonstrated that IgG and neutralizing antibodies against coronavirus associated with the severe acute respiratory syndrome (SARS) may persist, in spite of a decline in titer, for 2 years in patients who have recovered from SARS.

Fraudulent Coronavirus Disease 2019 (COVID-19) Products
https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019-covid-19-products

The U.S. Food and Drug Administration is issuing warning letters to firms for selling fraudulent products with claims to prevent, treat, mitigate, diagnose or cure coronavirus disease 2019 (COVID-19). We are actively monitoring for any firms marketing products with fraudulent COVID-19 prevention and treatment claims. The FDA is exercising its authority to protect consumers from firms selling un...

Colchicine as a possible therapeutic option in COVID-19 infection
https://link.springer.com/article/10.1007/s10067-020-05247-5

In contrast, we consider that colchicine can be a good therapeutic option because of several effects in the immunology system involved in SARS-CoV-2 infection and in the acute respiratory distress syndrome (ARDS). Colchicine has effects on the chemotaxis of inflammatory cells such as neutrophils and monocytes and on the intracellular transportation of vesicles such as endosomes and exosomes.

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
https://www.scripps.edu/_files/pdfs/news-and-events/The D614G mutation in the SARS-CoV-2 spike protein reduces S1.pdf

SARS coronavirus 2 (SARS-CoV-2) isolates encoding a D614G mutation in the viral spike (S) protein predominate over time in locales where it is found, implying that this change enhances viral transmission. We therefore compared the functional properties of the S proteins with aspartic acid (SD614) and glycine (SG614) at residue 614. We observed that retroviruses pseudotyped with SG614 infect...

Mutated coronavirus shows significant boost in infectivity
https://www.scripps.edu/news-and-events/press-room/2020/20200612-choe-farzan-coronavirus-spike-mutation.html

A tiny genetic mutation in the SARS coronavirus 2 variant circulating throughout Europe and the United States significantly increases the virus’ ability to infect cells, lab experiments performed at Scripps Research show.

A silent epidemic
https://news.harvard.edu/gazette/story/2020/04/one-third-of-hospitalized-covid-19-patients-show-signs-of-delirium/
Stephanie Dutchen

Geriatrician Sharon Inouye on the need to combat delirium in COVID-19 patients

Neurologic Features in Severe SARS-CoV-2 Infection
https://www.nejm.org/doi/full/10.1056/NEJMc2008597

We report the neurologic features in an observational series of 58 of 64 consecutive patients admitted to the hospital because of acute respiratory distress syndrome (ARDS) due to Covid-19. The patients received similar evaluations by intensivists in two intensive care units (ICUs) in Strasbourg, France, between March 3 and April 3, 2020.

‘They Want to Kill Me’: Many Covid Patients Have Terrifying Delirium
https://www.nytimes.com/2020/06/28/health/coronavirus-delirium-hallucinations.html

To a startling degree, many coronavirus patients are reporting similar experiences. Called hospital delirium, the phenomenon has previously been seen mostly in a subset of older patients, some of whom already had dementia, and in recent years, hospitals adopted measures to reduce it.

Delirium Incidence, Duration and Severity in Critically Ill Patients with COVID-19
https://www.medrxiv.org/content/10.1101/2020.05.31.20118679v1.full.pdf

Delirium incidence, duration and severity in patients admitted to the intensive care unit (ICU) due to COVID-19 is not known.

Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson’s Disease
https://www.e-jmd.org/upload/jmd-19082.pdf
Journal of Movement Disorders;

We recruited 228 drug-naïve PD patients who were followed for a mean of 6 years. Patients underwent the Cross-Cultural Smell Identification Test (CCSIT), a neuropsychological test, and N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane positron emission tomography within 6 months of the baseline evaluation. Olfactory dysfunction was categorized as normosmia (CCSIT score ≥ 9)...

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
https://www.frontiersin.org/articles/10.3389/fneur.2019.01217/full
Frontiers in Neurology;

Nov 20th, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon is especially pronounced in patients with Levodopa-induced dyskinesia (LID).

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achieving sustained testosterone suppression. Additionally, treatment was associated with faster testosterone recovery and decreased major adverse cardiovas...

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.